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Medically inoperable peripheral lung cancer
treated with stereotactic body radiation therapy
K. D. Kelley1, D. L. Benninghoff2, J. S. Stein3, J. Z. Li2, R. T. Byrnes2, L. Potters1, J. P. S. Knisely1 and H. D. Zinkin2,4*
Abstract
Background: Lung cancer is the most frequent cause of cancer-related death in North America. There is wide
variation between patients who are medically inoperable and those managed surgically. The use of stereotactic
body radiotherapy (SBRT) has narrowed the gap in survival rates between operative and non-operative management
for those with early stage disease. This retrospective study reports outcomes for the treatment of peripheral non-small
cell lung carcinoma (NSCLC) with SBRT from a single community practice.
Methods: Sixty-seven consecutive patients (pts) with inoperable, untreated peripheral lung tumors were treated from
2010 through 2012 and included in this study. Stereotactic targeting was facilitated by either spine or lung-based
image guidance, either with or without fiducial marker tracking with a frameless robotic radiosurgery system. Peripheral
tumors received a median biological effective dose (BED) of 105.6 Gy10 or in terms of a median physical dose, 48 Gy
delivered over 4 daily fractions. Survival was measured using the Kaplan-Meier method to determine rates of local
control, progression of disease and overall survival. The Cox proportional hazards regression model was used to study
the effects of tumor size, stage, histology, patient age, tumor location (lobe), tracking method, and BED on the survival
distributions.
Results: The median follow-up for this cohort was 24.5 months (range: 2.4–50.3) with an overall (OS) 3-year survival of
62.4 % (95 % CI: 74.3-47.3). The median progression-free survival was 28.5 months (95 % CI: 15.8 months to not
reached). Local control (LC), defined as a lack of FDG uptake on PET/CT or the absence of tumor growth was achieved
in 60 patients (90.9 %) at the time of first follow-up (median 3 months, range: 1–6). Local control at one year for the
entire cohort was 81.8 % (95 % CI, 67.3-90.3). The one-year OS probability among those who achieved local control at
first follow-up was 86.2 % (95 % CI, 74.3-92.9) but no patients who did not achieve LC at first follow-up survived one
year. Of the 60 pts that achieved initial LC, 16 have died. The rates of local control, progression-free survival and overall
survival were not statistically different for patients treated using a fiducial target tracking system versus non-invasive
guidance. (p = 0.44, p = 0.97 and p = 0.66, respectively). No National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE-4) grade 3 or greater toxicity was observed.
Conclusion: SBRT is an effective treatment for medically inoperable NSCLC patients with peripherally located tumors.
This therapy appears to be well tolerated with low toxicity, and patient outcomes when using non-invasive tumor
tracking systems are not inferior to traditional fiducial-based techniques.
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Background
Until the advent of stereotactic body radiation therapy
(SBRT), patients with early and intermediate stage lung
cancer who were medically inoperable had limited treat-
ment options [1]. Traditional protracted radiotherapy
yielded relatively poor outcomes for this patient popula-
tion historically with a 5-year overall survival of only
13–39 % [2]. Sophisticated treatment planning and
image guidance now permits focal high-dose per frac-
tion radiation to be delivered safely [3, 4]. This approach
of dose escalation delivered to a defined target while
preserving adjacent healthy tissues with strict geometric
avoidance of organs at risk (OARs) is what constitutes
SBRT. Clinical trials have shown an improvement of the
therapeutic ratio compared to results from conventional
radiotherapy with enhanced control rates and low tox-
icity to OARs [1, 5–11]. This approach has in turn
proven very effective in controlling tumors in medically
inoperable patients and is now considered a standard of
care for this patient population [1].
The purpose of this study was to analyze the outcomes
of patients treated with SBRT for early and intermediate
stage NSCLC within a community-based setting, in
order to outline potential prognostic factors and assess
variations in survival and local control rates when using
different methods of image guidance. Moreover, data an-
alyzed from a community-based practice may better esti-
mate non-academic centers’ outcomes and be more
representative of likely outcomes outside tertiary centers.
Additionally, lower dose per fraction regimens, similar
to those used in this study and known to carry less risk
of inducing acute and long-term toxicities, are hypothe-
sized to be more routinely used in a community setting,
as opposed to higher dose-escalation strategies reported
by many early multi-institutional series done at large
academic centers [1, 12].
Here we outline as our primary endpoint, all-cause
mortality reported as overall survival of the entire cohort
measured from the time of therapy completion. Other
endpoints include disease-free survival, local control, and
correlations between local control and overall survival
including tumor size, histology, tumor location, and treat-
ment technique.
Methods
Study approval was obtained from the North Shore-LIJ
Health System (NSLIJHS), Monter Cancer Center Scien-
tific Advisory Committee. A retrospective chart review
protocol was further reviewed and approved by the
NSLIJHS Institutional Review Board (IRB). Thereafter, a
database of all patients diagnosed with lung cancer and
treated with radiosurgery at North Shore Radiation
Therapy from 2010 to 2012 was created to allow for at
least a minimum of 2 years of follow-up. The following
variables were collected during the analysis: date of treat-
ment, patient age, tumor histology, tumor size, technique
of treatment, tumor location, length of follow-up, toxicity,
tumor control, and survival. IRB policies were followed
regarding data deidentification.
Radiotherapy technique and specifications
Due to the presence of a collaborative thoracic oncology
program with prospective review, each patient was evalu-
ated by a multidisciplinary team including a thoracic
surgeon, interventional radiologist, medical and radiation
oncologists. Patients were deemed medically inoperable
based on objective criteria including a FEV1 < 1.5 L, pre-
operative FEV1 < 40 % predicted value or DLCO <40 % of
predicted value and at the final discretion of the surgeon.
Many patients included in this study had fiducial markers
placed by interventional radiology at the time of tumor bi-
opsy unless they were deemed too high risk for this pro-
cedure. All patients were then simulated on a GE
Lightspeed 64 slice 4D CT simulator and treated at North
Shore Radiation Therapy/Cyberknife of Long Island. Tar-
get structures were delineated on pulmonary CT windows
with the aid of PET fusion. Avidity (a sustained uptake
value (SUV) of greater than 2) was included as part of
gross tumor volume (GTV). For patients without fiducial
markers or tumors not large enough to be seen and
tracked using orthogonal radiographs, a 4D CT of the
chest was used to account for tumor motion and create an
internal target volume (ITV). The ITV was expanded
3–5 mm to account for set up error and arrive at the plan-
ning target volume (PTV). The total dose was prescribed
to the 80 % isodose volume. The median biological BED
used in this study was 105.6 Gy (range, 180–85.5 Gy10).
Organs at risk and their respective tolerance doses used
during treatment planning are shown in Table 1.
Three image guidance systems onboard the Cyberknife
platform were used: the XSight Spine Tracking System,
which relies on bony anatomy of the spine to locate and
Table 1 Organ tolerance dose limits
Organ total dose volume
Spinal cord 22 Gy Maximum To any point
Esophagus 27 Gy maximum To any point
Brachial plexus 24 Gy maximum To any point
Aorta 45Gy maximum To any point
Heart 30Gy maximum To any point
Trachea and bronchus 30 Gy maximum To any point
Chest wall/ ribs 30 Gy maximuma To any point
Both lungs 20 Gy <10 % of organ volume
Both Lungs 15 Gy <35 % of organ volume
Skin 24 Gy maximuma To any point
aconsidered for superficial tumors < 2 cm from chest wall
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track tumors; the Synchrony Respiratory Motion Tracking
System, which continuously synchronizes beam delivery
with the motion of the target resulting from respiration by
using external fiducial markers as a surrogate to track
tumor motion; and the XSight Lung Tracking System,
which tracks the soft tissue (tumor) target with respiration
without the need for fiducial markers [13].
Statistical analysis
Statistical objectives of this study included the estimation
of median time until local progression, disease-free sur-
vival, all-cause mortality and acute toxicity. Survival was
measured using the Kaplan-Meier method to characterize
the progression of disease, local control and survival dis-
tributions. Median time to the event was estimated along
with a 95 % confidence interval (CI). The Cox propor-
tional hazards regression model was used to study the ef-
fects of multiple predictor variables (e.g. tumor size, stage,
histology, patient age, tumor location (lobe), tracking
method and biologic effective dose (BED)) on these three
time-until-event outcomes. Descriptive statistics (propor-
tions for categorical variables and means and standard
deviations for continuous variables) were also calculated.
Survival time was measured in months. Time until death
was calculated from date of treatment completion to
either date of event, or date of censoring (date of last
follow-up), except for local failure at first follow-up scan
post-treatment. In this case, time until death was mea-
sured from the date of first follow-up scan and not the
date of treatment completion. For disease-free survival,
failure was defined as any of the following: local failure,
regional failure, distant failure, or locoregional failure. In
cases where the event of death was not observed, the
number of months until last follow-up was used and the
subject’s vital status was classified as censored. The effects
of categorical demographic, clinical, pathologic, and treat-
ment variables were assessed using the log-rank test.
Univariate Cox regression was used for continuous vari-
ables. A result was considered statistically significant if the
p value was <0.05. To adjust for tied failure times, Efron’s
method was used [14].
End points and follow-up
Approximately three months after completing treatment,
a follow-up radiologic examination was performed to de-
termine the initial response to treatment. Two patients
were followed by a non-contrast CT and the remaining
with PET-CT scans. After the initial follow-up period, a
chest CT or PET-CT scan was done to evaluate both
tumor size and metabolism every 3 to 6 months for two
years post treatment ––after which follow-up was done
on an annual basis.
The definition of local control used in the current ana-
lysis was based on that used in RTOG 0236 [15]. Local
failure was defined as meeting any one of the following
criteria: (1) local tumor enlargement greater than 20 %
of the gross tumor volume compared to the treatment
planning CT-scan, (2) evidence of increasing metabolism
using PET imaging, or (3) development of a new lesion
in the involved lobe [15]. Regional failure was defined as
a recurrence within a different ipsilateral lobe or any
regional lymph node station including the bilateral hilar,
mediastinal, scalene, or supraclavicular nodal stations as
defined in the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual, 7th edition [16]. Distant
spread was defined as either radiographic evidence of a
malignant pleural or pericardial effusion, pleural-based
nodules, contralateral lung nodules, distant solid organ,
CNS or osseous involvement.
Results
A total of 67 medically inoperable patients with early
and intermediate stage lung cancer were treated with
stereotactic body radiotherapy (SBRT) between February
5, 2010 and November 4, 2013 (Table 2). Each patient
had a single peripheral tumor defined as at least 2 cm
from the trachea, carina and mainstem bronchi. One pa-
tient had limited follow-up, and was therefore included
only in the overall survival analysis. Of the remaining 66
patients: 43 had local control, 11 failed locally, 5 region-
ally, 2 distantly and 5 locoregionally. Twenty-two of the
67 subjects eventually died. Twenty-three of 66 subjects
had disease progression, and 6 had failed locally at the
time of initial post-treatment evaluation. The mean
follow-up was 24.5 months (range: 2.4-50.3 months).
Among subjects who remained alive or were censored,
the mean follow-up time was 28.6 months (range: 2.4-
50.3 months).
Overall survival based on local control status at first
follow-up
All patients were imaged 1–6 months (median 3 months)
after treatment. Due to the variability in how long after
treatment a first follow-up scan was obtained, a sensitiv-
ity analysis was performed whereby the actual follow-up
time from treatment to time of scan was adjusted for in
a Cox regression model with local control status at time
of first scan as the predictor of interest. The results from
this analysis (data not shown) were similar to the Kaplan
Meier estimate thus, only the Kaplan Meier results are
reported as representative of local control status.
The achievement of local control at the time of initial
follow-up was significantly associated with improved
overall survival. Local control data were available for 66
patients. Among the 60 patients with local control deter-
mined at first follow-up, 16/60 died, whereas all 6 of the
subjects who failed locally at their first follow-up scan suc-
cumbed to their disease. The estimated 1 year survival
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probability among patients achieving local control was
86.2 % (95 % CI, 74.3-92.9), whereas the one year survival
probability for patients with local failure at first follow-up
scan was 0.0 % (95 % CI, not estimable) (Fig. 1).
Local control, disease-free and overall survival rates
At 12 months, 81.8 % (95 % CI, 67.3-90.3) of patients
maintained local control out of the total cohort. However,
by 24 months only 60.6 % (95 % CI, 41.5- 75.2) of patients
had local control although the median time to local pro-
gression of disease was never reached (Fig. 2). The overall
disease-free survival at 3 years was 37.5 % (95 % CI: 17.7
to 57.4). Median disease-free survival was estimated to be
28.5 months (95 % CI: 15.8 months to not reached)
(Fig. 3a). The overall survival at 3 years was 62.4 % (95 %
CI: 74.3-47.3 %). The median overall survival time was not
reached during the designated follow-up period (Fig. 3b).
Comparative analysis of survival outcomes
A comparison of survival outcomes stratified by various
patient and treatment-specific factors was not found to
be statistically significant (using the log-rank test and
p < 0.05). For example, analysis of time until disease pro-
gression with respect to gender (p = 0.8), stage (p = 0.16),
pathology (p = 0.1), or tumor location/lobe involved
(p = 0.15) did not reveal any significant differences
(Additional file 1: Figure S1). Similarly, non-significant
results were found in Cox regression analyses for BED10
(p = 0.43), age (p = 0.15), and tumor size (p = 0.66) with
respect to disease-free survival (data not shown).
Kaplan-Meier analysis for time until death was not
found to be statistically significant among the following
subgroups by univariate analyses: gender (p = 0.13), stage
(p = 0.37), pathology (p = 0.77), and tumor location/lobe
(p = 0.81) (Additional file 2: Figure S2). Results from a
univariate Cox regression analysis did not provide statis-
tical evidence to suggest a difference in overall survival
according to BED10 (p = 0.08), age (p = 0.74), or tumor
size (p = 0.29) (data not shown).
Survival outcomes based on tracking method
A comparison of overall survival in patients stratified by
motion tracking and targeting system used during treat-
ment was also done. Either non-invasive image guidance
(XSight-spine/lung) alone or XSight-spine followed by
matching to surgically implanted-intratumoral fiducials
was used to localize and track tumors during each frac-
tion of treatment. In the latter technique, tumors were
initially aligned for treatment using the osseous spinal
anatomy of each patient as a surrogate (XSight-spine)
and then further adjusted through matching to radio-
opaque fiducials within the tumor. In the event that
tumor size was sufficient to visualize on orthogonal
radiographs, XSight-lung localization was utilized (3 pa-
tients out of 67) after an initial matching to a portion of
bony spine adjacent to the target. Survival was not found
to be statistically different in patients treated using
XSight-spine/lung compared to those treated with the
aid of XSight-spine localization with fiducials (Logrank,
p = 0.66). Additionally, there was no significant differ-
ence in local control or disease-free survival stratified by
any tumor tracking method (Logrank, p = 0.44 and
p = 0.97, respectively) (Fig. 4).
Treatment-related toxicity
Toxicity was assessed immediately after treatment and
again after 3 months of follow-up. Only four patients were
documented as developing grade 1 fatigue. No grade 2 or
higher toxicity was reported in this cohort at any time
(data not shown).
Discussion
In this study, medically inoperable patients with early or
intermediate-stage peripheral lung tumors were treated
with SBRT on a CyberKnife treatment platform to a range
Table 2 Patient characteristics (N = 67)
Age, years, median (range) 79 (60–92)
Sex Male n = 24 (36 %)
Female n = 43 (64 %)
Stage IA n = 52 (78 %)
IB-III n = 15 (22 %)
Location Left Lower lobe n = 16 (24 %)
Left Upper Lobe n = 16 (24 %)
Right Lower Lobe n = 12 (18 %)
Right Upper Lobe n = 23 (34 %)
Tumor volume <2.5 cc n = 17 (25 %)
5-2.5 cc n = 19 (29 %)
5-10 cc n = 7 (11 %)
10-20 cc n = 9 (13 %)
>20 cc n = 15 (22 %)
BED10
a Mean 107.8
Median (Range) 105.6 (180–85.5)
Tracking XSight-spine n = 30 (45 %)
XSight-lung n = 3 (5 %)
XSight-spine + Fiducials n = 34 (50 %)
Histology Adenocarcinoma n = 30 (44 %)
Squamous Cell Carcinoma n = 14 (21 %)
Non-small cell lung carcinoma-NOSb n = 14 (21 %)
Carcinoid n = 3 (4 %)
Sarcomatoid mesothelioma n = 1 (2 %)
Non-diagnostic biopsy n = 6 (8 %)
aBiologic Effective Dose, Gy10 or α/β ratio = 10
bNot otherwise specified
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Months 
Local failure at initial follow up 
Fig. 1 Achieving initial local control in previously untreated, medically inoperable patients with peripheral tumors targeted with SBRT is a
predictor for improved survival. Comparing patients that achieved local control at first follow-up scan after SBRT was significantly associated with
overall survival (OS) (p < 0.0001). OS at one year was 86.2 % (95 % CI, 74.3-92.9) in those achieving initial local control, whereas the one year
survival probability for patients with local failure at first follow-up scan was 0.0 % (95 % CI, not estimable)
Local control probability 
Fig. 2 Local control in previously untreated, medically inoperable patients with peripheral tumors after being treated with Cyberknife SBRT. Local
disease control at 12 months was 81.8 % (95 % CI, 67.3-90.3 %) and at 24 months was 60.6 % (95 % CI, 41.5- 75.2 %). The median time to local
progression of disease was not reached
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of biological effective doses (BED, 180–85.5 Gy10). The
overall survival in our cohort was similar to that achieved
in RTOG 0236 (62.4 % vs. 55.8 % at 36 months) [15]. Tox-
icity observed in this study, significant only for low grade
fatigue, was also improved when compared to earlier
studies—one of the first being the Indiana University
phase I dose escalation and feasibility trial with 5
treatment-related deaths (pneumonia (n = 3), respiratory
failure (n = 1), and hemoptysis (n = 1) occurring through-
out the study period out of 70 patients treated with lung
SBRT to a total dose of 60-66Gy in three fractions [12]. In
light of these findings, we selected more conservative
doses in an effort to balance the risk of toxicity with the
efficacy of tumor control. In addition, we selected lower
doses based on others’ observations reporting comparable
3 year local control rates above 80 % at 2 years using BEDs
A
B
Overall survival, in months  
Fig. 3 Disease free and overall survival in previously untreated patients with peripheral tumors deemed to be medically inoperable after being
treated with Cyberknife SBRT. a The median progression-free survival was estimated to be 28.5 months (95 % CI: 15.8 months to not reached).
The overall disease-free survival at 3 years was 37.5 % (95 % CI: 17.7- 57.4 %). b The overall survival at 3 years (36 months) was 62.4 % (95 % CI:
74.3-47.3 %). The median overall survival time was not reached
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C
Overall survival, in months 
Fig. 4 Comparing local control, disease free and overall survival rates in patients stratified by motion tracking system used during Cyberknife
SBRT. Either a fiducial free (Xsight-spine/lung) or fiducial-based (Xsight-spine + fiducials) tracking system was used to localize and track tumors
during each fraction of treatment. In the later technique, patients were initially aligned with Xsight-spine and then further adjusted through
matching to intratumoral fiducials. a Overall Survival at 24 months was not statistically different in patients treated using Xsight-spine 69.2 %
(95 % CL: 82.1-50.3 %) compared using Xsight-spine with fiducials 76.2 % (95 % CL: 88.6-58.0 %) (Logrank, p = 0.66) There was also no significant
difference in b local control at 24 months for Xsight-spine alone 72.2 % (95 % CL: 94.8-49.6 %) vs. Xsight-spine with fiducials 52.3 % (95 % CL:
75.4-29.7 %) (Logrank, p = 0.44) or c disease free survival at 24 months when comparing Xsight-spine alone 51.4 % (95 % CL: 73.1-24.3 %) vs.
Xsight-spine with fiducials, 52.3 % (95 % CL: 72.1-27.6 %) (Logrank, p = 0.97)
Table 3 Selected studies comparing local control as a function of BED
Author, year Stage Dose, BED10 Local control P value
Van der Voort van Zyp et al. 2009 [19] T1, n = 35; T2, n = 24 180 Gy 96 % at 2 years n.s. p = 0.197
112. 5 Gy 78 % at 2 years
Onimaru et al. 2008 [20] T1, n = 25; T2, n = 16 80 Gy 45 at 2 years p = 0.0042
105.6 Gy 89 % at 2 years
Guckenberger et al. 2009 [21] T1, n = 13; T2, n = 19; T3N0, n = 9 >100 Gy 89 % at 3 years p = 0.0001
<100 Gy 62 % at 3 years
Bibault et al. 2012 [6] T1, n = 31; T2, n = 20 ≤150 Gy 70 % at 2 years p = 0.006
>150 Gy 100 % at 2 years
Grills et al. 2012 [22] T1, n = 318; T2, n = 67; T3, n = 10 <105 Gy 85 % at 2 years p < 0.001
>105 Gy 96 % at 2 years
Onishi et al. 2007 [23] Stage I, n = 257 >100 Gy 84 % at 3 years p <0.01
<100 Gy 37 % at 3 years
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that approximate the range used in our cohort [17, 18]. In
spite of these efforts, local control was lower than ex-
pected when compared to these historic controls.
We found that indeed, the local control rate at
24 months had decreased to 60.6 % compared to 91 % at
three years seen in RTOG 0236 [15]. Although minor de-
viations in treatment planning may have contributed to
this observation, the lower BEDs employed in this study
are thought to be contributing factors compared to those
used in earlier studies such as the Indiana University
phase I dose escalation trial and RTOG 0236 where BEDs
used were considerably higher— approaching 151.2
Gy10 once tissue heterogeneity corrections were applied
[15, 12]. Furthermore, several others have reported that
dose escalation correlated directly with significantly
improved local control rates (Table 3) [6, 19–23]. It should
also be emphasized that 22 % of the patients included
in our cohort had stage IB to stage III disease and
RTOG 0236 included patients with only T1-T2 tumors.
Thus, it is possible that this may contribute to the
lower local control rate seen in this study. Nevertheless,
caution must be exercised when interpreting these
results due to the limitations implicit within a retro-
spective study such as this. An additional limitation of
this study is the relatively small sample size (n = 67
patients/treated lung tumors) which may explain the
lack of statistical significance seen when performing a
comparative analysis of survival outcomes to identify
predictive factors (Additional file 1: Figure S1 and
Additional file 2: Figure S2).
As anticipated, patients that had achieved local control
initially at the time of first follow-up had significantly
improved overall survival compared with those that did
not. These data support the notion that achieving initial
local tumor control is of critical importance for survival.
Ablative therapies such as SBRT are now routinely de-
signed without reliance on intra-target fiducial markers
since the advent of sophisticated onboard-non-invasive
image guidance systems [6, 13, 24]. Several phantom
studies have demonstrated the ability to achieve sub-
millimeter targeting with these systems [25]. However,
evidence supporting the use of fiducial-free image guid-
ance and localization systems is limited [6, 13, 25]. In
this analysis, through a side-by-side comparison, we
show that there is no difference statistically in survival
outcome or tumor control metrics when stratifying pa-
tients by tracking technique used. Thus, non-invasive
image-based tracking techniques appear to be safe and
effective alternatives compared with traditional fiducial-
based targeting and is in agreement with others’ reports
[13, 18, 24, 25]. This has important implications in
medically inoperable, frail patient populations with lung
cancer that may not be able to easily tolerate such inva-
sive procedures.
Conclusions
This study supports the role of SBRT in the treatment
paradigm for early-stage lung cancer in medically inop-
erable patients in order to gain local control of their dis-
ease, and doing so appears to be critical to achieving
prolonged overall survival in this patient population. It
provides evidence to justify the use of non-invasive
tumor targeting during treatment administration over
invasive fiducial-based targeting methods. Lastly, the im-
portance of dose escalation is emphasized by our results
especially with regard to the achievement of durable
local tumor control. Nevertheless, further studies evalu-
ating higher dose fractionation schemes are warranted to
reach a comfortable equilibrium between better local
control and low treatment-related morbidity.
Additional files
Additional file 1: Figure S1. Comparison of disease free survival rates
in patients stratified by gender, stage, pathology and location. The
different Kaplan-Meier curves for time until disease progression were not
found to be statistically significant (using the log-rank test and p < 0.05)
among the following subgroups in univariate analysis: (A) Gender at 24
months comparing male patients, 49.3 % (95 % CL: 71.7-22.4 %) to female
54.3 % (95 % CL: 73.6-29.6 %), (p = 0.8), (B) Stage at 24 months comparing
early stage patients with T1a disease 47.8 % (95 % CL: 64.9-28.5 %) to
those with intermediate stage IB-III disease, 64.3 % (95 % CL: 90.2-15.2 %),
(p = 0.16), (C) pathology at 24 months for patients with adenocarcinoma
41.4 % (95 % CL: 66.2-15.2 %), squamous cell carcinoma 30.3 % (95 % CL:
61.6-5.3 %), and unspecified non-small cell lung 64.3 % (95 % CL: 90.2-15.2 %),
(p = 0.1) or (D) tumor location within the left lower lobe (LL), 50.1 % (95 % CL:
77.7-15.1 %), left upper lobe (LU), 73.7 % (95 % CL: 91.3-35.9 %) right lower
lobe (RL), 28.3 % (95 % CL: 60.0-44.0 %), or right upper lobe (RU) 46.4 % (95 %
CL: 75.2-12.6 %), (p = 0.15).
Additional file 2: Figure S2. Comparison of overall survival rates in
patients stratified by gender, stage, pathology and location. The different
Kaplan-Meier curves for overall survival were not found to be statistically
significant (using the log-rank test and p < 0.05) among the following
subgroups in univariate analysis: (A) gender at 24 months comparing
male patients, 87.1 % (95 % CL: 95.7-65.0 %) to female patients 65.9 %
(95 % CL: 78.3-49.2 %) (p = 0.8), (B) stage at 24 months comparing early
stage patients with T1a disease 69.7 % (95 % CL: 80.5-55.7 %) to those
with intermediate stage IB-III disease, 86.7 % (95 % CL: 96.5-56.4 %)
(p = 0.37), (C) pathology at 24 months for patients with adenocarcinoma
75.4 % (95 % CL: 87.5-55.2 %), squamous cell carcinoma 71.4 % (95 % CL:
88.2-40.6 %), and unspecified non-small cell lung 70.7 % (95 % CL:
87.9-39.4 %) (p = 0.77), or (D) tumor location within the left lower lobe
(LL), 68.8 % (95 % CL: 85.6-40.5 %), left upper lobe (LU), 68.2 % (95 % CL:
85.4-39.5 %), right lower lobe (RL), 90.0 % (95 % CL: 98.5-47.3 %), or right
upper lobe (RU), 73.9 % (95 % CL: 87.3-50.9 %) (p = 0.81).
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